| 1 |
32786093 | Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties. | 2021 Jan |
1 |
| 2 |
33222389 | Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator-Induced Diaphragm Dysfunction in Rats. | 2021 Mar |
2 |
| 3 |
31217979 | Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. | 2019 Jun |
1 |
| 4 |
29115506 | Angiotensin II induces monocyte chemoattractant protein‑1 expression by increasing reactive oxygen species‑mediated activation of the nuclear factor‑κB signaling pathway in osteoblasts. | 2018 Jan |
2 |
| 5 |
29683146 | Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System. | 2018 Jan |
1 |
| 6 |
26067144 | [Enteropathy due to olmesartan]. | 2016 Apr |
1 |
| 7 |
26138656 | Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line. | 2016 Aug |
1 |
| 8 |
27086671 | Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). | 2016 Jun 20 |
2 |
| 9 |
27109007 | Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use. | 2016 Oct |
1 |
| 10 |
27129872 | [Enteropathy due to olmesartan]. | 2016 Sep |
1 |
| 11 |
27801805 | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients. | 2016 Oct 27 |
4 |
| 12 |
25561011 | Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure. | 2015 Apr |
1 |
| 13 |
25904217 | Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury. | 2015 Dec |
1 |
| 14 |
26240115 | The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. | 2015 Dec |
2 |
| 15 |
26330000 | Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line. | 2015 |
1 |
| 16 |
24290413 | Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects. | 2014 Jan |
1 |
| 17 |
23328189 | Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. | 2013 Feb |
1 |
| 18 |
23807874 | Evaluation of blood pressure control using a new arterial stiffness parameter, cardio-ankle vascular index (CAVI). | 2013 Feb |
1 |
| 19 |
24070321 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? | 2013 Nov |
1 |
| 20 |
24187471 | Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. | 2013 Oct 28 |
1 |
| 21 |
23052181 | Angiotensin II receptor blocker improves tumor necrosis factor-α-induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. | 2012 |
2 |
| 22 |
23430666 | Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. | 2012 Dec |
1 |
| 23 |
21767225 | The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. | 2011 Oct |
2 |
| 24 |
21881353 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. | 2011 |
3 |
| 25 |
19927151 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. | 2010 Feb |
5 |
| 26 |
20508392 | Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways. | 2010 |
7 |
| 27 |
20829713 | Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. | 2010 Nov |
1 |
| 28 |
19689219 | Olmesartan medoxomil: recent clinical and experimental acquisitions. | 2009 Sep |
2 |
| 29 |
18547134 | Olmesartan medoxomil: a review of its use in the management of hypertension. | 2008 |
2 |
| 30 |
23355126 | Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism : Focus on Olmesartan Medoxomil. | 2008 Oct |
1 |
| 31 |
17380010 | Angiotensin II inhibits insulin-induced actin stress fiber formation and glucose uptake via ERK1/2. | 2007 Feb |
1 |
| 32 |
17404186 | Regulation of scavenger receptor class BI gene expression by angiotensin II in vascular endothelial cells. | 2007 Jun |
2 |
| 33 |
17803345 | Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design. | 2007 |
2 |
| 34 |
16948472 | Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2. | 2006 May |
1 |
| 35 |
15695623 | Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. | 2005 May |
2 |
| 36 |
16081869 | Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. | 2005 Sep 2 |
1 |
| 37 |
16321616 | Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. | 2005 Nov |
3 |
| 38 |
15313950 | Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. | 2004 Aug 31 |
1 |
| 39 |
12503943 | Olmesartan medoxomil: the seventh angiotensin receptor antagonist. | 2003 Jan |
2 |
| 40 |
14668930 | Olmesartan, an AT1-selective antihypertensive agent. | 2003 Oct |
1 |
| 41 |
11967728 | The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. | 2002 May |
2 |
| 42 |
11116149 | Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. | 2001 Mar 16 |
1 |
| 43 |
11451210 | Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. | 2001 Jun |
1 |
| 44 |
11451214 | Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. | 2001 Jun |
1 |
| 45 |
11768722 | Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. | 2001 Nov |
1 |